PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Tattooing hair loss drugs like minoxidil and dutasteride into the scalp is discussed as an alternative to daily pills, with mixed opinions on its effectiveness and convenience. Some users report positive results, but concerns about cost, potential side effects, and the procedure's discomfort are noted.
A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.
A new topical Dutasteride with 20 times better scalp absorption being developed and tested for release in 2023; use of existing drugs, such as Minoxidil and finasteride; and mesotherapy as an alternative hair loss treatment.